Safety and immunogenicity of a combination diphtheria-tetanus toxoids-acellular pertussis-hepatitis B vaccine administered at two, four and six months of age compared with monovalent hepatitis B vaccine administered at birth, one month and six months of age

Pediatric Infectious Disease Journal

Volumn 21, Issue 8, 2002, Pages 769-776

  Greenberg, David P ^a   Wong, Victor K ^b   Partridge, Susan ^c   Howe, Barbara J ^d   Ward, Joel I ^c  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b KAISER PERMANENTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; ORAL POLIOMYELITIS VACCINE; TETANUS TOXOID;

APPETITE DISORDER; ARTICLE; DIARRHEA; DIPHTHERIA; DRUG INDUCED DISEASE; DRUG SAFETY; FEVER; HEPATITIS B; HUMAN; IMMUNOGENICITY; INFANT; INFLUENZA; MAJOR CLINICAL STUDY; POLIOMYELITIS; PRIORITY JOURNAL; SLEEP DISORDER; TETANUS; VACCINATION; VOMITING;

AGE FACTORS; ANTIBODIES, VIRAL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNIZATION; INFANT; INFANT, NEWBORN; POLIOVIRUS;

EID: 0036678168     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200208000-00014     Document Type: Article

References (33)

1. Universal hepatitis B immunization
2. Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: Recommendations of the Immunization Practices Advisory Committee
3. Feasibility study of a combined diphtheria-tetanus-acellular pertussis-hepatitis B (DTPa-HBV) vaccine, and comparison of clinical reactions and immune responses with diphtheria-tetanusacellular pertussis (DTPa) and hepatitis B vaccines applied as mixed or injected into separate limbs
4. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-hepatitis B vaccine administered according to two different primary vaccination schedules
5. Comparison study of the immunogenicity and safety of 5- and 10-μg dosages of a recombinant hepatitis B vaccine in healthy infants
6. Comparative safety and immunogenicity of two recombinant hepatitis B vaccines given to infants at two, four, and six months of age
7. Hepatitis B vaccine
8. Acellular pertussis diphtheria-tetanus-pertussis vaccine containing separately purified pertussis toxoid, filamentous haemagglutinin and 69kDa outer membrane protein as a booster in children
9. Estimation of Corynebacterium diphtheriae antitoxin in human sera: A comparison of an enzyme-linked immunosorbent assay with the toxin neutralisation test
10. A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera
11. Radio-immunoassay for serum Haemophilus influenzae type b capsular polysaccharide (Hib CP) antibodies
12. Response to hepatitis B vaccine in young adults population: Viral hepatitis and liver diseases
13. Twelve-year follow-up study of hepatitis B immunization of Senegalese infants
14. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men
15. A 9-year follow-up study of the immunogenicity and long-term efficacy of plasma-derived hepatitis B vaccine in high-risk Chinese neonates
16. Long term immune response of universal hepatitis B vaccination in infancy: A community-based study in Taiwan
17. Protection provided by hepatitis B vaccine in a Yupik Eskimo population: Results of a 10-year study
18. Hepatitis B vaccination in high-risk infants: 10-Year follow-up
19. The prevention of hepatitis B with vaccine: Report of the Centers for Disease Control multi-center efficacy trial among homosexual men
20. Hepatitis B vaccine: Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States
21. Long-term efficacy of plasma-derived hepatitis B vaccine: A 15-year follow-up study among Chinese children
22. Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen
23. Persistence of anti-HBs in children vaccinated against viral hepatitis B in the first year of life: Follow-up at 5 and 10 years
24. Booster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose
25. Comparative study of the immunogenicity and safety of two dosing schedules of Engerix-B® hepatitis B vaccine in neonates
26. Clinical experience with hepatitis B vaccine
27. Immunogenicity of a combined diphtheria-tetanus-acellular pertussis (DT-tricomponent Pa)-hepatitis B (HB)-inactivated poliovirus (IPV) admixed with Haemophilus influenzae type b (Hib) vaccine in infants
28. Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants
29. Inactivated poliovirus vaccine alone or sequential inactivated and oral poliovirus vaccine in two-, four- and six-month-old infants with combination Haemophilus influenzae type b/hepatitis B vaccine
30. A new DTPa-HBV-IPV vaccine co-administered with Hib, compared with a commercially available DTPw-IPV/Hib vaccine co-administered with HBV, given at 6, 10 and 14 weeks following HBV at birth
31. Immunogenicity and safety of a new liquid hexavalent combined vaccine compared with separate administration of reference licensed vaccines in infants
32. Safety and immunogenicity of a combination DTPa-hepatitis B vaccine (DTPa-Hep B) administered to infants at 2, 4 and 6 months of age